跳至主要内容
临床试验/NCT00110435
NCT00110435已完成3 期

A Multicenter, Randomized, Double-blind, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypercholesterolemia

Organon and Co0 个研究点目标入组 1,229 人开始时间: 2005年5月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
1,229
主要终点
Percent reduction in LDL-C from baseline after 6 weeks of treatment

研究概览

简要总结

The purpose of this 10-week study is to compare the reduction in cholesterol following treatment with two different marketed drugs, in patients with type 2 diabetes mellitus and hypercholesterolemia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 79 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men and women aged 18 to 79 years who have a confirmed diagnosis of type 2 diabetes mellitus with elevated cholesterol levels may be eligible to participate in a study to assess the efficacy and safety of the two marketed drugs.

排除标准

  • Type 1 Diabetes Mellitus
  • Type 2 Diabetes Mellitus that is poorly controlled

结局指标

主要结局

Percent reduction in LDL-C from baseline after 6 weeks of treatment

次要结局

  • Percent of patients attaining LDL-C <70 mg/dl after 6 weeks of treatment

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

A Multicenter Study to Evaluate the Cholesterol... | 临床试验